NovoCure Limited (FRA:038)
10.59
-0.25 (-2.35%)
Last updated: Jan 28, 2026, 8:12 AM CET
NovoCure Revenue
NovoCure had revenue of $167.20M USD in the quarter ending September 30, 2025, with 7.81% growth. This brings the company's revenue in the last twelve months to $642.27M, up 11.17% year-over-year. In the year 2024, NovoCure had annual revenue of $605.22M with 18.82% growth.
Revenue (ttm)
$642.27M
Revenue Growth
+11.17%
P/S Ratio
2.14
Revenue / Employee
$431.63K
Employees
1,488
Market Cap
1.17B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.66M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gelsenwasser AG | 3.36B |
| Paul Hartmann AG | 2.44B |
| FRoSTA Aktiengesellschaft | 652.00M |
| tonies SE | 510.38M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| Südwestdeutsche Salzwerke AG | 347.96M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |
NovoCure News
- 17 days ago - NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 20 days ago - Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update - Business Wire
- 4 weeks ago - NovoCure: 2026 Pipeline Outlook Makes This Stock A Speculative Buy - Seeking Alpha
- 5 weeks ago - NovoCure (NVCR) Q4 2024 Earnings Call Transcript - The Motley Fool
- 5 weeks ago - NovoCure (NVCR) Q3 2024 Earnings Call Transcript - The Motley Fool
- 5 weeks ago - Novocure (NVCR) Q2 2025 Earnings Call Transcript - The Motley Fool
- 5 weeks ago - First Week of February 2026 Options Trading For NovoCure (NVCR) - Nasdaq
- 5 weeks ago - Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire